<p>根據 Donoghue Forlines LLC 最近向證券交易委員會提交的文件，該公司在第一季度購買了 Eli Lilly and Company（紐約證券交易所代碼：LLY - 免費報告）的新股份。這家機構投資者購買了 2,737 股該公司的股票，價值約為 2,261,000 美元。</p>
<p>獲取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
<ul>
<li>特朗普 GLP-1 試點計劃可能會推動諾和諾德和 Eli Lilly 的增長</li>
</ul>
<p>其他幾家大型投資者也對該公司的持股進行了調整。WestEnd Advisors LLC 在第一季度將其在 Eli Lilly and Company 的持股增加了 210.0%。WestEnd Advisors LLC 現在擁有 31 股該公司的股票，價值 26,000 美元，此前在該期間又購買了 21 股。Citizens National Bank Trust Department 在第一季度將其在 Eli Lilly and Company 的持股提高了 180.0%。Citizens National Bank Trust Department 現在擁有 42 股該公司的股票，價值 35,000 美元，此前在該期間又購買了 27 股。Financial Gravity Asset Management Inc.在第一季度購買了 Eli Lilly and Company 的新股份，價值約為 40,000 美元。Mascagni Wealth Management Inc.在第四季度購買了 Eli Lilly and Company 的新股份，價值 43,000 美元。最後，O Brien Wealth Partners LLC 在第一季度將其在 Eli Lilly and Company 的持股增加了 25.5%。O Brien Wealth Partners LLC 現在擁有 59 股該公司的股票，價值 49,000 美元，此前在上個季度又購買了 12 股。機構投資者和對沖基金持有該公司 82.53% 的股票。</p>
<h2>華爾街分析師預測增長</h2>
<p>多家研究公司最近對 LLY 發表了評論。摩根士丹利在 7 月 10 日的報告中重申了 “增持” 評級，並將 Eli Lilly and Company 的目標股價設定為 1,135.00 美元（上調自 1,133.00 美元）。富國銀行在 5 月 1 日的報告中重申了對 Eli Lilly and Company 的 “增持” 評級。滙豐全球研究在 4 月 28 日的報告中將 Eli Lilly and Company 的評級從 “強力買入” 下調至 “適度賣出”。Cantor Fitzgerald 在 4 月 22 日的報告中開始覆蓋 Eli Lilly and Company 的股票。他們給予了 “增持” 評級，並設定了 975.00 美元的目標價。最後，Wall Street Zen 在 7 月 26 日的報告中將 Eli Lilly and Company 的評級從 “持有” 上調至 “買入”。一位研究分析師對該股票給予了賣出評級，五位分析師給予了持有評級，十七位分析師給予了買入評級。根據 MarketBeat 的數據，Eli Lilly and Company 目前的平均評級為 “適度買入”，平均目標價為 990.89 美元。</p>
<ul>
<li>Eli Lilly 在財報發佈後的 14% 下滑是否是買入機會？</li>
</ul>
<p><strong>查看我們關於 LLY 的最新報告</strong></p>
<h2>Eli Lilly and Company 股票表現</h2>
<p>LLY 在週五開盤價為 625.15 美元。該公司的流動比率為 1.37，速動比率為 1.06，債務與股本比率為 2.18。該公司的市值為 5924.8 億美元，市盈率為 40.86，PEG 比率為 0.91，貝塔值為 0.44。該公司的 50 日移動平均線為 774.10 美元，200 日移動平均線為 798.80 美元。Eli Lilly and Company 的 12 個月低點為 623.78 美元，12 個月高點為 972.53 美元。</p>
<ul>
<li>諾和諾德股票下跌——但底部終於到來了嗎？</li>
</ul>
<p>Eli Lilly and Company（紐約證券交易所代碼：LLY - 獲取免費報告）最近在 8 月 7 日發佈了季度財報。該公司報告每股收益（EPS）為 6.31 美元，超出分析師一致預期的 5.59 美元，超出幅度為 0.72 美元。Eli Lilly and Company 的淨利潤率為 25.91%，股本回報率為 98.25%。該公司本季度的收入為 155.6 億美元，而一致預期為 144.0 億美元。去年同期，該公司每股收益為 3.92 美元。與去年同期相比，該公司的收入增長了 37.6%。平均而言，股票研究分析師預測 Eli Lilly and Company 在當前年度將發佈 23.48 美元的每股收益。</p>
<h2>Eli Lilly and Company 股息公告</h2>
<p>該公司最近還宣佈了一項季度股息，將於 9 月 10 日（星期三）支付。8 月 15 日（星期五）的股東將獲得每股 1.50 美元的股息。該股息的除息日期為 8 月 15 日（星期五）。這代表着每年 6.00 美元的股息和 1.0% 的收益率。Eli Lilly and Company 目前的派息比率為 48.82%。</p>
<h2>內部人士下注</h2>
<p>在其他新聞中，董事 Jamere Jackson 在 8 月 8 日（星期五）的一筆交易中購買了 200 股該股票。這些股票的平均購買價格為每股 639.56 美元，總價值為 127,912.00 美元。完成收購後，該董事直接持有 9,402 股該公司的股票，價值 6,013,143.12 美元。這筆交易代表了他們持股的 2.17% 的增加。該收購在向 SEC 的法律文件中披露，相關文件可通過 SEC 網站獲取。0.13% 的股票由公司內部人士持有。</p>
<h2>Eli Lilly and Company 簡介</h2>
<p>（免費報告）</p>
<p>Eli Lilly and Company 在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素利普羅、胰島素利普羅原料、胰島素利普羅混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；以及 Zepbound 用於肥胖。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過禮來公司</li>
<li>擁有債券的風險</li>
<li>愛彼迎超出預期盈利，但增長故事正在失去高度</li>
<li>最活躍的股票：美元交易量與股數交易量</li>
<li>Netflix 多頭與空頭：誰將在這次回調中獲勝？</li>
<li>3 只前景良好的金融科技股票</li>
<li>Viasat：為什麼一大筆現金讓空頭們紛紛逃避</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在禮來公司嗎？</h2>
<p>在考慮禮來公司之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前購買的股票……而禮來公司並不在名單上。</p>
<p>雖然禮來公司目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

禮來

<p>Donoghue Forlines LLC 在第一季度通過收購 2,737 股投資了 226 萬美元於禮來公司（NYSE: LLY）。其他機構投資者也增加了對該公司的持股。禮來的股票獲得了分析師的多次評級，平均評級為 “適度買入”，目標價格為 990.89 美元。該公司報告了強勁的季度收益，超出預期，並宣佈每股派發 1.50 美元的季度股息，支付日期為 9 月 10 日</p>

<p>Donoghue Forlines LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 2,737 shares of the company's stock, valued at approximately $2,261,000.</p>
<div class="lb-trans"><p>根據 Donoghue Forlines LLC 最近向證券交易委員會提交的文件，該公司在第一季度購買了 Eli Lilly and Company（紐約證券交易所代碼：LLY - 免費報告）的新股份。這家機構投資者購買了 2,737 股該公司的股票，價值約為 2,261,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
</div><ul>
<li>Trump GLP-1 Pilot Program Could Boost Novo Nordisk &amp; Eli Lilly</li>
</ul>
<div class="lb-trans"><ul>
<li>特朗普 GLP-1 試點計劃可能會推動諾和諾德和 Eli Lilly 的增長</li>
</ul>
</div><p>Several other large investors have also made changes to their positions in the company. WestEnd Advisors LLC grew its holdings in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares during the period. Citizens National Bank Trust Department raised its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new stake in Eli Lilly and Company during the 1st quarter worth approximately $40,000. Mascagni Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $43,000. Finally, O Brien Wealth Partners LLC boosted its stake in shares of Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家大型投資者也對該公司的持股進行了調整。WestEnd Advisors LLC 在第一季度將其在 Eli Lilly and Company 的持股增加了 210.0%。WestEnd Advisors LLC 現在擁有 31 股該公司的股票，價值 26,000 美元，此前在該期間又購買了 21 股。Citizens National Bank Trust Department 在第一季度將其在 Eli Lilly and Company 的持股提高了 180.0%。Citizens National Bank Trust Department 現在擁有 42 股該公司的股票，價值 35,000 美元，此前在該期間又購買了 27 股。Financial Gravity Asset Management Inc.在第一季度購買了 Eli Lilly and Company 的新股份，價值約為 40,000 美元。Mascagni Wealth Management Inc.在第四季度購買了 Eli Lilly and Company 的新股份，價值 43,000 美元。最後，O Brien Wealth Partners LLC 在第一季度將其在 Eli Lilly and Company 的持股增加了 25.5%。O Brien Wealth Partners LLC 現在擁有 59 股該公司的股票，價值 49,000 美元，此前在上個季度又購買了 12 股。機構投資者和對沖基金持有該公司 82.53% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of research firms recently commented on LLY. Morgan Stanley reiterated an &#34;overweight&#34; rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Wells Fargo &amp; Company reiterated an &#34;overweight&#34; rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Hsbc Global Res lowered shares of Eli Lilly and Company from a &#34;strong-buy&#34; rating to a &#34;moderate sell&#34; rating in a report on Monday, April 28th. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an &#34;overweight&#34; rating and a $975.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, July 26th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $990.89.</p>
<div class="lb-trans"><p>多家研究公司最近對 LLY 發表了評論。摩根士丹利在 7 月 10 日的報告中重申了 “增持” 評級，並將 Eli Lilly and Company 的目標股價設定為 1,135.00 美元（上調自 1,133.00 美元）。富國銀行在 5 月 1 日的報告中重申了對 Eli Lilly and Company 的 “增持” 評級。滙豐全球研究在 4 月 28 日的報告中將 Eli Lilly and Company 的評級從 “強力買入” 下調至 “適度賣出”。Cantor Fitzgerald 在 4 月 22 日的報告中開始覆蓋 Eli Lilly and Company 的股票。他們給予了 “增持” 評級，並設定了 975.00 美元的目標價。最後，Wall Street Zen 在 7 月 26 日的報告中將 Eli Lilly and Company 的評級從 “持有” 上調至 “買入”。一位研究分析師對該股票給予了賣出評級，五位分析師給予了持有評級，十七位分析師給予了買入評級。根據 MarketBeat 的數據，Eli Lilly and Company 目前的平均評級為 “適度買入”，平均目標價為 990.89 美元。</p>
</div><ul>
<li>Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?</li>
</ul>
<div class="lb-trans"><ul>
<li>Eli Lilly 在財報發佈後的 14% 下滑是否是買入機會？</li>
</ul>
</div><p><strong>Check Out Our Latest Report on LLY</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 LLY 的最新報告</strong></p>
</div><h2>Eli Lilly and Company Stock Performance</h2>
<div class="lb-trans"><h2>Eli Lilly and Company 股票表現</h2>
</div><p>LLY opened at $625.15 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company has a market cap of $592.48 billion, a price-to-earnings ratio of 40.86, a PEG ratio of 0.91 and a beta of 0.44. The company's 50 day moving average is $774.10 and its 200 day moving average is $798.80. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $972.53.</p>
<div class="lb-trans"><p>LLY 在週五開盤價為 625.15 美元。該公司的流動比率為 1.37，速動比率為 1.06，債務與股本比率為 2.18。該公司的市值為 5924.8 億美元，市盈率為 40.86，PEG 比率為 0.91，貝塔值為 0.44。該公司的 50 日移動平均線為 774.10 美元，200 日移動平均線為 798.80 美元。Eli Lilly and Company 的 12 個月低點為 623.78 美元，12 個月高點為 972.53 美元。</p>
</div><ul>
<li>Novo Nordisk Stock Sinks—But Is a Bottom Finally In?</li>
</ul>
<div class="lb-trans"><ul>
<li>諾和諾德股票下跌——但底部終於到來了嗎？</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 98.25%. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the firm posted $3.92 earnings per share. The firm's revenue was up 37.6% compared to the same quarter last year. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.</p>
<div class="lb-trans"><p>Eli Lilly and Company（紐約證券交易所代碼：LLY - 獲取免費報告）最近在 8 月 7 日發佈了季度財報。該公司報告每股收益（EPS）為 6.31 美元，超出分析師一致預期的 5.59 美元，超出幅度為 0.72 美元。Eli Lilly and Company 的淨利潤率為 25.91%，股本回報率為 98.25%。該公司本季度的收入為 155.6 億美元，而一致預期為 144.0 億美元。去年同期，該公司每股收益為 3.92 美元。與去年同期相比，該公司的收入增長了 37.6%。平均而言，股票研究分析師預測 Eli Lilly and Company 在當前年度將發佈 23.48 美元的每股收益。</p>
</div><h2>Eli Lilly and Company Dividend Announcement</h2>
<div class="lb-trans"><h2>Eli Lilly and Company 股息公告</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 1.0%. Eli Lilly and Company's payout ratio is currently 48.82%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度股息，將於 9 月 10 日（星期三）支付。8 月 15 日（星期五）的股東將獲得每股 1.50 美元的股息。該股息的除息日期為 8 月 15 日（星期五）。這代表着每年 6.00 美元的股息和 1.0% 的收益率。Eli Lilly and Company 目前的派息比率為 48.82%。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, Director Jamere Jackson purchased 200 shares of the stock in a transaction on Friday, August 8th. The shares were acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.13% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新聞中，董事 Jamere Jackson 在 8 月 8 日（星期五）的一筆交易中購買了 200 股該股票。這些股票的平均購買價格為每股 639.56 美元，總價值為 127,912.00 美元。完成收購後，該董事直接持有 9,402 股該公司的股票，價值 6,013,143.12 美元。這筆交易代表了他們持股的 2.17% 的增加。該收購在向 SEC 的法律文件中披露，相關文件可通過 SEC 網站獲取。0.13% 的股票由公司內部人士持有。</p>
</div><h2>Eli Lilly and Company Profile</h2>
<div class="lb-trans"><h2>Eli Lilly and Company 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>Eli Lilly and Company 在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素利普羅、胰島素利普羅原料、胰島素利普羅混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；以及 Zepbound 用於肥胖。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>The Risks of Owning Bonds</li>
<li>Airbnb Beats Earnings, But the Growth Story Is Losing Altitude</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>Netflix Bulls vs. Bears: Who Wins This Pullback?</li>
<li>3 Fintech Stocks With Good 2021 Prospects</li>
<li>Viasat: Why a Wall of Cash Has Shorts Running for Cover</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過禮來公司</li>
<li>擁有債券的風險</li>
<li>愛彼迎超出預期盈利，但增長故事正在失去高度</li>
<li>最活躍的股票：美元交易量與股數交易量</li>
<li>Netflix 多頭與空頭：誰將在這次回調中獲勝？</li>
<li>3 只前景良好的金融科技股票</li>
<li>Viasat：為什麼一大筆現金讓空頭們紛紛逃避</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在禮來公司嗎？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮禮來公司之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前購買的股票……而禮來公司並不在名單上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然禮來公司目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Donoghue Forlines LLC 對禮來公司（NYSE: LLY）進行了新的 226 萬美元投資